OBJECTIVE： To provide references for perfecting online drug trading regulatory policy in China. METHODS： The online drug trading regulatory evolutions in China were summarized. The characteristics of network drug trading management in China and the existing problems were analyzed to put forward regulatory suggestions. RESULTS & CONCLUSIONS： The online drug trading regulation in China had gone through four stages including on-line drug selling prohibition， piloting， exploration of regulatory evolution and the regulation challenge under “Internet plus Health Care” era. It had been transited from prior-supervision of permission to in-process/post-supervision with a characteristic of high-speed and imbalanced development. The author participated in the investigation of the online-drug trading companies and basic level regulatory authority， found existing issues such as counterfeit drug selling by internet， the blind zone for regulation of third-party drug logistics and cross-border logistics， lacking of standardization for drug information display and so on. It is suggested that the legislation of online drug trading regulatory should be in accordance with the thinking of revising higher-level law as Drug Administration Law； the regulatory relationship between drug management and circulation needs to be defined； the prescription drug online sale should match remote diagnosis and treatment system； regulatory capacity was further expounded by exploring the new network technique to regulation， establishing a standard database of drug， strengthening logistics and distribution supervision， exerting the review obligations of third-party platforms， and strengthening the training of regulators to further improve  the management  of  online drug trading regulatory policy in China.